TNF - a NING YALLIG‘LANISH JARAYONIDAGI ROLI VA GURUHLARARO DINAMIK TAHLILI NATIJALARI
Xakimov I. S., Xaydarova G. S. & Xakimova S. B.
Annotatsiya
O`sma nekroz faktori alfa ( TNF - α) – bu organizmdagi yallig‘lanish jarayonlarini boshqarishda muhim rol o‘ynaydigan asosiy proinflammator sitokinlardan biridir TNF - α ni asosan faollashgan makrofaglar, T-limfotsitlar va boshqa immun hujayralar ishlab chiqaradi. Jarohat yoki jarrohlik aralashuvidan so‘ng TNF - α darajasi juda tez oshadi va erta yallig‘lanish javobini shakllantiradi. Tadqiqotlar shuni ko‘rsatadiki, TNF - α boshqa bir qator yallig‘lanish mediatorlarini (masalan, IL-6, IL-8 kabi interleykinlarni) ishlab chiqilishini kuchaytirishi mumkin, shu tariqa yallig‘lanish kaskadini yanada kengaytiradi. Shu sababli TNF - α darajasini aniqlash jarrohlikdan keyingi yallig‘lanish darajasini baholashda muhim biomarker hisoblanadi. TNF - α miqdori yallig‘lanish reaksiyasining kuchi va davomiyligini aks ettirib, jarohat olgan to‘qimalarda immun javob qanchalik kuchayganini ko‘rsatadi. TNF - α ning yallig‘lanish davridagi dinamik o‘zgarishlari. Oddiy sharoitda, jarohat yoki septoplastika jarrohlik amaliyotidan keyin TNF - α darajasi juda tez, bir necha soat ichida ko‘tariladi va taxminan bir sutkada eng yuqori cho‘qqiga yetadi . Keyinchalik, agar asoratlanmagan sog‘ayish jarayoni kechsa, TNF - α sekretsiyasi pasayib boradi – odatda uchinchi kunga kelib sezilarli darajada kamayadi va beshinchi kunga kelib me’yorga yaqinlashadi . TNF - α ning bunday qisqa muddatli cho‘qqi ko‘rinishi uning “erta javob mediatatori” ekanligini, ya’ni jarohatga javoban dastlabki yallig‘lanish bosqichini qo‘zg‘atuvchi vosita ekanligini ko‘rsatadi. Keyingi davrlarda TNF - α pasayishi bilan birga boshqa yallig‘lanish omillar (masalan, interleykinlar) faoliyati ham pasayib, to‘qimalarning tuzalish bosqichiga o‘tiladi. Shu nuqtai nazardan, septoplastika jarrohlik amaliyotidan keyingi davrda TNF - α darajasining qanchalik tez me’yorga qaytishi yallig‘lanishning tezlik bilan bosilishini va shikastlangan to‘qimalarning normal holatga qaytishini bildiradi .
Adabiyotlar
- Fokkens W.J., Hoffmans R., Thomas M. Avoid prescribing antibiotics in acute rhinosinusitis. // BMJ. – 2014 – 349 – P. 57-63.
- Halawi AM, Smith SS, Chandra RK. Chronic rhinosinusitis: epidemiology and cost. Allergy Asthma Proc. 2013;34(4):328334. Doi:10.2500/aap.2013.34.3675
- Halderman A. Genetic and Immune Dysregulation in Chronic Rhinosinusitis / A. Halderman, Lane A.P.// Otolaryngol Clin North Am 2017. Vol.50. N.1.. P. 13-28
- Hansen M.P., Hoffmann T.С., mccullough A.R., van Driel M.L., Del Mar C.В. Antibiotic Resistance: What are the Opportunities for Primary Care in Alleviating the Crisis? Front Public Health. 2015;3:35. Doi:10.3389/fpubh.2015.00035
- Heffler E., Malvezzi L., Boita M., Brussino L., De Virgilio A., Ferrando M., et al. Immunological mechanisms underlying chronic rhinosinusitis with nasal polyps. Expert Rev Clin Immunol. 2018;14(9):731-737. Doi: 10.1080/1744666X.2018.1512407
- Hopkins C., Rudmik L. Disparities in grant funding for Chronic rhinosinusitis. // Laryngoscope. – 2015 - 126(4) – P. 136140.
- Hulse K.E. Immune Mechanisms of Chronic Rhinosinusitis. Curr Allergy Asthma Rep. 2016;16(1):1. Doi: 10.1007/s11882-015-0579-0.
- Human antimicrobial use report, 2012/2013. Government of Canada. Guelph ON: Public Health Agency of Canada; 2014. Available at: http:www. Wormsandgermsblog.com/.../canadianhu
- Husain S., Amilia H.H., Rosli M.N. et al on behalf of Development Group Clinical Practice Guidelines Management of Rhinosinusitis in Adolescents & Adults. Management of rhinosinusitis in adults in primary care. // Malays Fam Physician. – 2018 - 13(1) – P. 28–33.
- Izquierdo-Domínguez A., Valero A.L., Mullol J. Comparative analysis of allergic rhinitis in children and adults. Curr. Allergy Asthma Rep, 2013 Apr, 13(2): 142-141.
- Irsalieva, F.,Dustbabaeva, N.,Kamalov, Z.,Ziyadullaev, Shukhrat.,Nurmatova, N.Akhmedov, Zh.2020/10/15/IL17A rs2275913 polymorphism and features of immunological parameters in patients with persistent allergic rhinitis during allergen-specific immunotherapy/ 10.46235/1028-7221-440
- Jorgensen LC, Friis Christensen S, Cordoba Currea G, Llor C, Bjerrum L. Antibiotic prescribing in patients with acute rhinosinusitis is not in agreement with European recommendations. Scand J Prim Health Care. 2013;31(2):101105. Doi:10.3109/02813432.2013.788270
- Kim D.W., Cho S.H. Emerging Endotypes of Chronic Rhinosinusitis and Its Application to Precision Medicine. Allergy Asthma Immunol Res. 2017;9(4):299-306. Doi: 10.4168/ aair.2017.9.4.299.
- Limon L., Kockler D.R. Desloratadine: a nonsedating antihistamine. Ann Pharmacother, 2013,37(2): 237-246.
- Lund V.J. Impact of chronic rhinosinusitis on quality of life and health care expenditure. // Clin Allergy Immunol. – 2017 – №20 – P. 15-24.
- Magnan A., Romanet S., Vervloet D. Rhinitis, nasosinusalpoliposis and asthma: clinical aspects. The Nose and Lung Diseases. Ed. by B Wallaert, P Chanez, P Godard. Eur. Resp. Monograph. 2011: 101-115.
- Madeo J., Frieri M. Bacterial biofilms and chronic rhinosinusitis. Allergy Asthma Proc. 2013;34(4):335341. Doi:10.2500/aap.2013.34.3665
- Mazza J.M. Primary immunodeficiency and recalcitrant chronic sinusitis: asystematic review / J.M. Mazza, S.Y. Lin //Int Forum Allergy Rhinol. 2016. Vol.6. № 10. P.1029-1033
- Mcmahon S.B. Crosstalk between the nociceptive and immune systems in host defence and disease / S.B.mcmahon, F.L. Russa, D.L. Bennett D.L.// Nat. Rev. Neurosci. 2015. Vol.16. N.17. P. 389-402
- Meltzer E.O., Hamilos D.L., Hadley J.A., Lanza D., Marple B.F., Nicklas R.A., Bachert C., Baraniuk J., Baroody F.M., Benninger M.S., Brook I., Chowdhury B.A., Druce H.M., Durham S., Ferguson B., Gwaltney J.M., Kaliner M., Kennedy D.W., Lund V., Naclerio R., Pawankar R., Piccirillo J.F., Rohane P., Simon R., Slavin R.G., Togias A.,Wald E.R., Zinreich S.J. Rhinosinusitis: establishing definitions for clinical research and patient care. Otolaryngol Head Neck Surg. 2014;114(6, Suppl):155212. Doi: 10.1016/j.jaci.2004.09.029.